View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 11, 2022

FDA grants Orphan Drug status to Aro Biotherapeutics’ Pompe disease therapy

The company plans to advance ABX1100 into clinical trials in the middle of next year.

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation for Aro Biotherapeutics’ ABX1100 to treat Pompe disease.

An investigational Centyrin-small interfering ribonucleic acid (siRNA) conjugate, ABX1100 acts on the glycogen synthase 1 (Gys1) gene in the muscle.

​Gys1 is an enzyme that synthesises glycogen in muscle. Hindering this enzyme was found to lower glycogen levels and is a new approach to treat Pompe disease.

In a Pompe mouse disease model, ABX1100 was demonstrated to greatly reduce the Gys1 mRNA and GYS1 protein, causing a meaningful decline in glycogen levels in the skeletal muscle.

The company plans to advance ABX1100 into clinical trials in the middle of next year.

Aro Biotherapeutics chief medical officer Mittie Doyle said: “We are pleased to have received this designation and are gratified by the FDA’s recognition of the potential of ABX1100 to improve the lives of patients living with Pompe disease.

“We believe our novel treatment approach has the opportunity to address the great unmet need that exists in Pompe disease, and we are excited to advance ABX1100 to clinical trials in the coming year.”

A biotechnology firm, Aro Biotherapeutics focuses on developing tissue-targeted genetic treatments.

Pompe disease is a rare genetic ailment that causes debilitating weakness of muscles which advances over time.

It is caused by a mutation in the acid alpha-glucosidase (GAA) enzyme, which disintegrates glycogen in the muscle.

Due to the mutation, Pompe disease patients have increased glycogen levels which leads to the progression of the ailment.

At present, patients receive enzyme replacement therapy (ERT) with recombinant GAA given intravenously.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper
img

Optimise your cell therapy process: a guide to cell thawing

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology